Claims

1. A combination, comprising:

as a first active ingredient, 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a ~~prodrug or~~ pharmaceutically acceptable salt thereof, and ~~as a second active ingredient pyronaridine or a prodrug or pharmaceutically acceptable salt thereof.~~

as a second active ingredient, pyronaridine or a pharmaceutically acceptable salt thereof.

2. ~~A~~The combination according to claim 1, which further comprises:

as a third active ingredient, artemisinin or a derivative or pharmaceutically acceptable salt thereof.

3. ~~A~~ The combination according to claim 2, wherein the artemisinin derivative is selected from ~~a~~the group consisting of~~:~~ dihydroartemisin ~~and~~, artemether, and artesunate.

4. ~~A~~The combination according to claim 3, ~~which~~ wherein the third active ingredient is artesunate or a pharmaceutically acceptable salt thereof.

5. ~~A~~The combination according to claim 4, wherein the pharmaceutically acceptable salt of artesunate is salt selected from ~~a~~the group consisting of~~:~~ sodium salts and potassium salts.

6. ~~A~~ The combination according to ~~any of claims~~claim 2 ~~to 5~~, wherein the combination comprises:

6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide, ~~pyronaridine tetraphosphate and sodium artesunate.~~

pyronaridine tetraphosphate, and

sodium artesunate.

7. ~~A~~ The combination according to ~~any of claims~~claim 1 ~~to 6~~, wherein the first active ~~ingredients~~ingredient and the second active ingredient are administered simultaneously or sequentially.

~~8. A combination comprising according to any of claims 1 to 7 for use in the treatment and/or prevention of malaria.~~

~~9.~~

8. A pharmaceutical composition, comprising:

as active ingredients,

therapeutically active doses of 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a ~~prodrug or~~ pharmaceutically acceptable salt thereof, and ~~pyronaridine or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient, for the treatment and/or prevention of malaria.~~

~~10. A~~pyronaridine or a pharmaceutically acceptable salt thereof, and

at least one pharmaceutically acceptable excipient,

for the treatment and/or prevention of malaria.

9. The pharmaceutical composition according to claim ~~9~~8, comprising:

as a further active ingredient, a therapeutically active dose of artemisinin or a derivative or pharmaceutically acceptable salt thereof.

~~11.~~

10. A kit for the treatment of malaria, comprising:

firstly 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a pharmaceutically active salt thereof, and ~~secondly pyronaridine or a pharmaceutically active salt thereof.~~

~~12. A~~secondly pyronaridine or a pharmaceutically active salt thereof.

11. The kit according to claim ~~11~~10, which further comprises:

artemisinin or a derivative or pharmaceutically acceptable salt thereof.

~~13. A method for the treatment and/or prevention of malaria in a patient in need thereof, comprising administering to such patient~~

12. Use of a therapeutically active amount of a combination of 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide ~~and pyronaridine~~ or a ~~prodrug or~~ pharmaceutically acceptable salt ~~of any of the any of the foregoing including mixtures~~ thereof ~~in all ratios.~~, and

pyronaridine or a pharmaceutically acceptable salt thereof, including mixtures thereof in all ratios, in the manufacture of a medicament for the treatment and/or prevention of malaria in a patient in need thereof, wherein said medicament is to be administered to such patent.

13. The use according to claim 12, wherein the combination further comprises artemisinin or a derivative or pharmaceutically acceptable salt thereof.